Pacific Edge (ASX: PEB) reported a modest 2.7% sequential increase in Q4 FY26 test volumes, driven by new commercial payer coverage and anticipated Medicare policy momentum.
Total laboratory throughput increased to 5,582 tests in Q4 FY26, with US volumes rising 1.0% to 4,064 tests and Asia Pacific volumes up 7.7% to 1,518 tests.
New commercial payer coverage was secured for Cxbladder Triage by BCBS North Carolina (covering approximately 3.4 million lives) and BCBS South Carolina (approximately 0.762 million lives).
Additionally, Cxbladder Monitor gained coverage by Highmark (covering 7 million lives).
Despite operational disruptions from winter storms and a reduced sales force that decreased to 7.7 full-time equivalents from 12.0 FTEs in Q3 FY26, tests per sales FTE rose to 530 from 335.
Medicare Policy Momentum Builds
The company reiterated expectations for a draft Medicare local coverage determination (LCD) for Cxbladder Triage/Triage Plus before the end of Q2 FY27, and even potentially before the end of September 2026.
Final-effective coverage is anticipated about six months thereafter.
A Novitas Contractor Advisory Committee (CAC) meeting on 19 February 2026 demonstrated strong expert support for Cxbladder Triage.
This indicates potential for favourable coverage through the Medicare policy process.
Progress also continues in Medicare appeals, with the first hearing for Cxbladder Triage denials scheduled for 24 February 2026.
Strategic Partnerships and IP Advance
In the Asia Pacific region, Singapore General Hospital has incorporated Triage, Triage Plus, and Monitor, while Townsville University Hospital began clinical use of Triage Plus and Monitor.
A Patent Cooperation Treaty (PCT) application was filed for Cxbladder Triage Plus in March 2026.
This action preserves a March 2025 US provisional priority date, targeting multi-jurisdiction patent protection.
Preliminary data from the AUSSIE study received the Best Oncology Presentation award at USANZ 2026.
Publication of this data is targeted for September 2026.
Navigating Sales Headwinds
Q3 FY26 saw a 13.4% decline in total laboratory throughput, primarily attributed to the US customer transition from Cxbladder Detect to Triage.
Ongoing US Medicare non-coverage and a seasonal holiday slowdown also contributed to these sales headwinds.
Previous context included a trading halt in February 2026 ahead of the Novitas CAC meeting.
The company also appointed Simon Flood as Chair Designate in December 2025 to help steer through regulatory uncertainty.
US regulatory risks, including proposed FDA changes for laboratory-developed tests (LDTs), remain a background consideration for medtech firms operating in the market.
The Bottom Line
Pacific Edge demonstrated sequential volume growth in Q4 FY26, boosted by expanding commercial payer coverage and positive developments in its Medicare reimbursement pathway.
While sales capacity has been reduced and US transitions created headwinds, the company's focus on clinical evidence and regulatory milestones, particularly the anticipated Medicare LCD, presents a key catalyst for future growth.
